ArticleExperimental hematology2018
Aptamer-based proteomics of serum and plasma in acquired aplastic anemia.
Article in Experimental hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.Circulation. Heart failure · 2022Trial
- Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies.International journal of laboratory hematology · 2026Article
- Multi-omics and artificial intelligence for precision drug discovery and potential clinical applications.Signal transduction and targeted therapy · 2026Review
- Circulating T Regulatory Cells Are Persistently Reduced in Non-Severe Acquired Aplastic Anemia.Current medical science · 2025Article
- Immature forms of low density granulocytes are increased in acute myeloid leukemia and myelodysplastic syndromes.Scientific reports · 2025Article
- Addressing statistical challenges in the analysis of proteomics data with extremely small sample size: a simulation study.BMC genomics · 2024Article
- All Roads Lead to Interferon-γ: From Known to Untraveled Pathways in Acquired Aplastic Anemia.Medicina (Kaunas, Lithuania) · 2023Review
- The application of Aptamer in biomarker discovery.Biomarker research · 2023Review
- Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases.Molecules (Basel, Switzerland) · 2022Review
- Proteome-Wide Analysis Using SOMAscan Identifies and Validates Epidermal Growth Factor as a Disease Marker of Collagenous Gastritis.Gastro hep advances · 2022Article
- Bone Marrow Failure Syndromes, Overlapping Diseases with a Common Cytokine Signature.International journal of molecular sciences · 2021Review
- Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification.Molecular & cellular proteomics : MCP · 2021Review
- Advances in Aptamer-Based Biomarker Discovery.Frontiers in cell and developmental biology · 2021Review
- Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases.International journal of molecular sciences · 2020Review
- Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value in Multiple Sclerosis.Frontiers in neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Single-stranded oligonucleotides containing deoxyuridine are aptamers (SOMAmers) that can bind proteins with high specificity and affinity and slow dissociation rates. SOMAscan, an aptamer-based proteomic technology, allows measurement of more than 1,300 proteins simultaneously for the identification of new disease biomarkers. The aim of the present study was to identify new serum and plasma protein markers for diagnosis of acquired aplastic anemia (AA) and response to immunosuppressive therapies (IST). SOMAscan was used to screen 1,141 serum proteins in 28 AA patients before and after therapy and 1,317 plasma proteins in seven SAA patients treated with standard IST and a thrombopoietin receptor agonist. From our analysis, 19 serum and 28 plasma proteins were identified as possible candidate diagnostic and prognostic markers. A custom immunobead-based multiplex assay with five selected serum proteins (BMP-10, CCL17, DKK1, HGF, and SELL) was used for validation in a verification set (n = 65) of samples obtained before and after IST and in a blinded validation cohort at baseline (n = 16). After technical validation, four biomarkers were employed to predict diagnosis (accuracy, 88%) and long-term response to IST (accuracy, 79%). In conclusion, SOMAscan is a powerful tool for the identification of new biomarkers. We propose further larger studies to validate new candidate serum and plasma diagnostic and prognostic markers of AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.